Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,033.90USD
14 Nov 2017
Change (% chg)

-- (--)
Prev Close
$1,033.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,362
52-wk High
$1,100.00
52-wk Low
$788.70

Latest Key Developments (Source: Significant Developments)

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 08:45am EST 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Bristol-Myers and Syngene expand ongoing research collaboration
Tuesday, 14 Nov 2017 09:44am EST 

Nov 14 (Reuters) - Syngene International ::Bristol-Myers Squibb and Syngene International expand ongoing research collaboration.Says collaboration with Bristol-Myers Squibb extended until 2026​.  Full Article

Syngene International ‍expands collaboration with Bristol-Myers Squibb​
Monday, 13 Nov 2017 10:06pm EST 

Nov 14 (Reuters) - Syngene International Ltd ::Says ‍expanded collaboration with Bristol-Myers Squibb​.Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​.  Full Article

Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study
Friday, 10 Nov 2017 07:00am EST 

Nov 10 (Reuters) - Bristol-myers Squibb Co :Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003.Bristol-Myers Squibb Co - ‍In dose escalation phase, maximum tolerated dose (primary endpoint) of BMS-986205 in combination with Opdivo was 200mg​.  Full Article

U.S. Food and Drug Administration expands approval of Sprycel (dasatinib)
Friday, 10 Nov 2017 06:30am EST 

Nov 10 (Reuters) - Bristol-myers Squibb Co ::U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) to include treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.Approval based on data from prospective trial in pediatric chronic myeloid leukemia in chronic phase​.Co says ‍continues to explore pediatric applications for investigational oncology agents within its broad development program​.Approval for Sprycel granted under priority review, indication received Orphan Drug Designation from FDA.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels
Tuesday, 7 Nov 2017 08:35am EST 

Nov 7 (Reuters) - Bristol-myers Squibb Co :Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.Bristol-Myers Squibb Co - ‍Safety profile of Opdivo plus Yervoy was consistent with that of previous reports​.Bristol-Myers Squibb - ‍Median OS was not reached for Opdivo plus Yervoy cobo or sunitinib for those with PD-l1 levels <1%, and for patients with PD-l1 expression levels ≥1% ​.  Full Article

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

FDA approves roll-over combination study of BriaVax with pembrolizumab
Monday, 30 Oct 2017 08:30am EDT 

Oct 30 (Reuters) - Briacell Therapeutics Corp :FDA approves the roll-over combination study with checkpoint inhibitor immunotherapies to allow continued access to BriaVax in patients with advanced breast cancer.Briacell Therapeutics - ‍FDA approved roll-over combination study of BriaVax with pembrolizumab or ipilimumab.Briacell- ‍FDA approved roll-over combination study for patients previously treated with BriaVax from Phase I/IIa clinical trial in advanced breast cancer​.  Full Article

Bristol-Myers Squibb reports Q3 earnings per share $0.51
Thursday, 26 Oct 2017 06:59am EDT 

Oct 26 (Reuters) - Bristol-Myers Squibb Co ::Q3 GAAP earnings per share $0.51; Q3 non-GAAP earnings per share $0.75; Q3 revenues up 7 percent to $5.3 billion.Decreasing 2017 GAAP earnings per share guidance range from $2.66 - $2.76 to $2.36 - $2.46.Increasing 2017 non-GAAP earnings per share guidance range from $2.90 - $3.00 to $2.95 - $3.05.Sees 2017 gross margin as a percentage of revenue to be about 71.5 percent for GAAP.Sees 2017 research and development expenses increasing about 25 pct - 30 pct compared to 2016 for GAAP.Qtrly Opdivo worldwide revenues $1,265 million versus $920 million last year.Qtrly Sprycel worldwide revenues $509 million versus $472 million last year.Qtrly Yervoy worldwide revenues $323 million versus $285 million last year.Qtrly Eliquis worldwide revenues $1,232 million versus $884 million last year.FY2017 earnings per share view $2.99 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.77, revenue view $5.20 billion -- Thomson Reuters I/B/E/S.  Full Article

Photo

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.